DGAP-News: Fresenius Medical Care AG & Co. KGaA reports

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: Fresenius Medical Care AG & Co. KGaA reports strong operating results for the third quarter 2014 and confirms guidance for full year 2014

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous Fresenius Medical Care AG & Co. KGaA reports strong operating results for the third quarter 2014 and confirms guidance for full year 2014 04.11.2014 / 07:23 --------------------------------------------------------------------- Fresenius Medical Care reports strong operating results for the third quarter 2014 and confirms guidance for full year 2014 - Third quarter shows strong organic revenue growth - Operating cash flow on record level in third quarter - Company remains on track to achieve full year guidance Third quarter 2014 key figures: Net revenue $4,113 million +12% Operating income (EBIT) $590 million +6% Net income $271 million -1% Basic earnings per share $0.89 -1% First nine months 2014 key figures: Net revenue $11,511 million +7% Operating income (EBIT) $1,591 million 0% Net income $710 million -7% Basic earnings per share $2.35 -6% Rice Powell, chief executive officer of Fresenius Medical Care stated: "The third quarter has confirmed the positive trend from the previous quarter. Growth rates in revenue and earnings again improved and our operating cash flow has reached an all time high for a single quarter. We are on track to achieve our guidance as well as our cost savings target for the full year. The recent acquisitions, in combination with financing activities were important steps in the execution of our strategy to achieve our long term target 2020." Third quarter 2014 Revenue Net revenue for the third quarter of 2014 increased by 12% to $4,113 million (+13% at constant currency) as compared to the third quarter of 2013. Organic revenue growth worldwide was 7%. Dialysis services revenue grew by 14% to $3,197 million (+15% at constant currency) and dialysis product revenue increased by 7% to $916 million (+7% at constant currency) as compared to the third quarter of 2013. North America revenue for the third quarter of 2014 increased by 11% to $2,710 million. Organic revenue growth was 5%. Dialysis services revenue grew by 12% to $2,498 million with a same store treatment growth of 3.5%. Dialysis product revenue was flat compared to the third quarter of 2013 at $212 million. International revenue increased by 13% to $1,386 million (+16% at constant currency). Organic revenue growth was 8%. Dialysis services revenue increased by 19% to $699 million (+25% at constant currency). Dialysis product revenue increased by 9% to $687 million (+9% at constant currency). Earnings Operating income (EBIT) for the third quarter of 2014 increased by 6% to $590 million as compared to $557 million in the third quarter of 2013. Operating income for North America for the third quarter of 2014 was $413 million, flat as compared to the third quarter of 2013. In the International segment, operating income for the third quarter of 2014 increased by 26% to $269 million as compared to $214 million in the third quarter of 2013. Net interest expense for the third quarter of 2014 was $99 million, compared to $103 million in the third quarter of 2013. Income tax expense was $162 million for the third quarter of 2014, which translates into an effective tax rate of 32.9%. This compares to income tax expense of $148 million and a tax rate of 32.6% for the third quarter of 2013. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA for the third quarter of 2014 was $271 million, a decrease of 1% compared to the corresponding number of $273 million for the third quarter of 2013. Basic earnings per share (EPS) for the third quarter of 2014 was $0.89, a decrease of 1% compared to the corresponding number for the third quarter of 2013. The weighted average number of shares outstanding for the third quarter of 2014 was approximately 302.7 million shares, compared to 301.3 million shares for the third quarter of 2013. The increase in shares outstanding resulted from stock option exercises in the past twelve months. Cash flow In the third quarter of 2014, the company generated $712 million in net cash provided by operating activities, an increase of 18% compared to the corresponding figure of last year and representing 17% of revenue. A total of $224 million was spent for capital expenditures, net of disposals. Free cash flow was $488 million compared to $430 million in the third quarter of 2013. A total of $613 million in cash was spent for acquisitions and investments, net of divestitures. Free cash flow after investing activities was a negative $125 million as compared to $235 million in the third quarter of 2013. First nine months 2014 Revenue and earnings Net revenue for the first nine months of 2014 increased by 7% to $11,511 million (+8% at constant currency) as compared to the first nine months of 2013. Organic revenue growth worldwide was 5%. Operating income (EBIT) for the first nine months of 2014 was $1,591 million as compared to $1,595 million in the first nine months of 2013. Net interest expense for the first nine months of 2014 was $294 million as compared to $310 million in the first nine months of 2013. Income tax expense for the first nine months of 2014 was $440 million, which translates into an effective tax rate of 33.9%. This compares to income tax expense of $421 million and a tax rate of 32.8% for the first nine months of 2013. For the first nine months of 2014, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA was $710 million, down by 7% from the corresponding number of $761 million for the first nine months of 2013. In the first nine months of 2014, basic earnings per share (EPS) was $2.35, a decrease of 6% compared to the corresponding number for the first nine months of 2013. The weighted average number of shares outstanding during the first nine months of 2014 was approximately 302.0 million shares. Cash flow In the first nine months of 2014, the company generated $1,274 million in net cash provided by operating activities as compared to $1,446 million for the same period in 2013 and representing 11% of revenue. A total of $639 million was spent for capital expenditures, net of disposals. Free cash flow for the first nine months of 2014 was $635 million as compared to $952 million in the first nine months of 2013. A total of $1,045 million in cash was spent for acquisitions and investments, net of divestitures. Free cash flow after investing activities was a negative $410 million as compared to $673 million in the first nine months of 2013. Employees As of September 30, 2014, Fresenius Medical Care had 97,327 employees (full-time equivalents) worldwide, compared to 89,282 employees at the end of September 2013. This increase of more than 8,000 employees was attributable to acquisitions as well as to our continued organic growth. Balance sheet structure The company's total assets were $24,253 million (Dec. 31, 2013: $23,120 million), an increase of 5%. Current assets increased by 3% to $6,459 million (Dec. 31, 2013: $6,287 million). Non-current assets were $17,794 million (Dec. 31, 2013: $16,833 million), an increase of 6%. Total equity increased by 3% to $9,750 million (Dec. 31, 2013: $9,485 million). The equity ratio was 40% as compared to 41% at the end of 2013. Total debt was $9,068 million (Dec. 31, 2013: $8,417 million). As of September 30, 2014, the debt/EBITDA ratio was 3.0 (Dec. 31, 2013: 2.8). Please refer to the attachments for a complete overview of the results for the third quarter and first nine months of 2014 and the reconciliation of non-GAAP financial measures included in this release to the most comparable GAAP financial measures. Outlook The company expects revenue to be at around $15.2 billion in 2014, translating into a growth rate of around 4%. This outlook excludes revenue of approximately $500 million from acquisitions completed during the first nine months of 2014. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be unchanged between $1.0 billion and $1.05 billion in 2014. The company initiated a global efficiency program designed to enhance the company's performance over a multi-year period. Potential cost savings, before income taxes, of up to $60 million generated from this program, and net of implementation costs are not included in the outlook for 2014. For 2014, the company expects to spend around $900 million on capital expenditures. Reflecting the latest acquisitions the company now expects acquisition spending of around $1.3 billion for fiscal year 2014 (previously $1 billion). The debt/EBITDA ratio is expected to be around 3.0 by the end of 2014. Conference call Fresenius Medical Care will hold a conference call to discuss the results of the third quarter 2014 on Tuesday, November 4, 2014 at 3.30 p.m. CET/ 9.30 a.m. EST. The company invites investors to follow the live webcast of the call at the company's website www.fmc-ag.com in the "Investor Relations" section. A replay will be available shortly after the call. Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.5 million individuals worldwide. Through its network of 3,349 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 283,135 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care, visit the company's website at www.fmc-ag.com. Disclaimer This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. CONTACT Fresenius Medical Care AG & Co. KGaA Investor Relations 61352 Bad Homburg v. d. H. Germany www.fmc-ag.com Oliver Maier Head of Investor Relations & Corporate Communications Tel. +49 6172 609 2601 Fax +49 6172 609 2301 email: ir@fmc-ag.com Published by Fresenius Medical Care AG & Co. KGaA Investor Relations Annual reports, interim reports and further information on the company is also available on our website. Please visit us at www.fmc-ag.com For printed material, please contact Investor Relations. --------------------------------------------------------------------- 04.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany Phone: +49 (0) 6172- 609 2525 Fax: +49 (0) 6172- 609 2301 E-mail: ir@fmc-ag.com Internet: www.fmc-ag.de ISIN: DE0005785802, DE0005785836, WKN: 578580, 578583 Indices: DAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart; Terminbörse EUREX; NYSE End of News DGAP News-Service --------------------------------------------------------------------- 294808 04.11.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 70

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 10

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 6

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 228

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 56

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 91

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading

Top 5 Most Recently Viewed Articles

Embracing Harmony and Cooperation in Today's World

Updated Category News Views 99

Understanding the Essence of Hehe Culture The concept of "Hehe" in Chinese culture symbolizes harmony, peace, and cooperation, deeply embedded in the collective mindset. This philosophy, with roots extending over thousands of years, emphasizes living in balance not only with one another but also with nature and oneself. The teachings of Hehe are particularly significant...

Continue Reading
Current Trends in Mortgage Rates and Home Buying Activity

Updated Category News Views 184

The average rate for a 30-year fixed-rate mortgage dropped to 6.08% in 2024, hitting its lowest point in two years. This slight decrease from 6.09% the previous week caught the eye of potential home buyers and homeowners considering refinancing. In contrast, the average rate for a 15-year mortgage ticked up by a single basis point to reach 5.16%. These small fluctuations...

Continue Reading
Mueller Water Products Engages at 2024 Baird Industrial Conference

Updated Category News Views 195

Mueller Water Products to Engage in the Baird Industrial Conference Mueller Water Products, Inc. (NYSE: MWA), headquartered in Atlanta, is set to participate in the Baird 2024 Global Industrial Conference. This prestigious event will take place in a vibrant city known for its industrial drive and innovation. Mueller’s management team is looking forward to sharing...

Continue Reading
SANY Showcases Advanced Eco-Friendly Solutions at bauma

Updated Category News Views 389

SANY Showcases Advanced Eco-Friendly Solutions at bauma The 34th bauma, recognized as the world's leading trade fair for construction machinery, recently wrapped up in Munich. This year's theme was "The World of Efficiency, Your Partner to Create the Best", and SANY Group, in collaboration with Putzmeister, put forth an impressive display of cutting-edge technology and...

Continue Reading
Orbit International Corp Completes $1 Million Power Supply Order

Updated Category News Views 182

Orbit International Corp Secures Major Follow-On Order Orbit International Corp. (OTCID Basic Market: ORBT), a prominent player in electronic manufacturing and software solutions, has announced the receipt of a new order valued at approximately $1,000,000. This order, secured by its Orbit Power Group (OPG), pertains to a commercial power supply that is utilized in...

Continue Reading